Ex­clu­sive: Jnana says piv­otal tri­al of PKU pill could be­gin next year af­ter promis­ing re­sults from a small­er study

Jnana Ther­a­peu­tics, a Boston start­up that’s look­ing to tack­le a rare meta­bol­ic dis­ease, has re­port­ed promis­ing re­sults from an on­go­ing ear­ly clin­i­cal tri­al, giv­ing it line-of-sight to jump straight in­to a piv­otal study in 2025, the com­pa­ny told End­points News in an in­ter­view.

The study test­ed a twice-dai­ly pill in adults with phenylke­tonuria, or PKU, an in­her­it­ed dis­ease that leaves peo­ple un­able to break down a pro­tein build­ing block called pheny­lala­nine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER